Oryzon Genomics SA Sustainability Reports

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a leader in the development of epigenetics-based therapeutics. The company focuses on personalized medicine approaches for oncology, hematology, and central nervous system disorders.

Sector: Manufacturing

Country: Spain

Exchange: Bolsa de Madrid (BME)

ISIN: ES0167733015

12 reports from 2015 to 2025

• Oryzon Genomics SA 2025 Annual Corporate Governance Report
• Oryzon Genomics SA 2024 Annual Corporate Governance Report
• Oryzon Genomics SA 2023 Annual Corporate Governance Report
• Oryzon Genomics SA 2022 Annual Corporate Governance Report
• Oryzon Genomics SA 2021 Annual Corporate Governance Report